ReviewPediatric cardiology2015
Current Views on Anthracycline Cardiotoxicity in Childhood Cancer Survivors.
Review in Pediatric cardiology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 54 citations in OpenAlex.
- Heart failure in long-term survivors of childhood cancer - a systematic review and meta-analysis of population-based studies.Acta oncologica (Stockholm, Sweden) · 2025Pooled it
- Occurrence of Treatment-Related Cardiotoxicity and Its Impact on Outcomes Among Children Treated in the AAML0531 Clinical Trial: A Report From the Children's Oncology Group.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2019Trial
- Dexrazoxane Cardioprotection in pediatric ALL: a historical control cohort study.Cardio-oncology (London, England) · 2026Article
- Potent immune-dependent anticancer effects of the non-cardiotoxic anthracycline aclarubicin.Oncoimmunology · 2025Review
- Anthracycline-induced hypertension in pediatric cancer survivors: unveiling the long-term cardiovascular risks.The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology · 2024Review
- A Comprehensive Review of Cancer Drug-Induced Cardiotoxicity in Blood Cancer Patients: Current Perspectives and Therapeutic Strategies.Current treatment options in oncology · 2024Review
- Re-Exploring the Anthracycline Chemical Space for Better Anti-Cancer Compounds.Journal of medicinal chemistry · 2023Article
- Assessment of Cardiovascular Function in Childhood Leukemia Survivors: The Role of the Right Heart.Children (Basel, Switzerland) · 2022Article
- The Therapeutic Potential of Carnosine as an Antidote against Drug-Induced Cardiotoxicity and Neurotoxicity: Focus on Nrf2 Pathway.Molecules (Basel, Switzerland) · 2022Review
- Approaches for monitoring and treating cardiomyopathy among cancer survivors following anthracycline or thoracic radiation treatment.Cardio-oncology (London, England) · 2022Article
- Heart failure in childhood cancer survivors-a systematic review protocol.Systematic reviews · 2022Article
- Anthracycline Treatment and Left Atrial Function in Children: A Real-Time 3-Dimensional Echocardiographic Study.Pediatric cardiology · 2022Article
- Article
- The Value of Left Atrial Volume Changes in Predicting Cardiotoxicity in Patients Undergoing Anthracycline Chemotherapy.Journal of healthcare engineering · 2022Article
- Risk Factors of Daunorubicine Induced Early Cardiotoxicity in Childhood Acute Lymphoblastic Leukemia: A Retrospective Study.Asian Pacific journal of cancer prevention : APJCP · 2021Article
- Doxorubicin and Aclarubicin: Shuffling Anthracycline Glycans for Improved Anticancer Agents.Journal of medicinal chemistry · 2020Article
- Uncoupling DNA damage from chromatin damage to detoxify doxorubicin.Proceedings of the National Academy of Sciences of the United States of America · 2020Article
- PET Radiopharmaceuticals for Imaging Chemotherapy-Induced Cardiotoxicity.Current cardiology reports · 2020Review
- Cardio-toxicity in childhood cancer survivors "Cure is not enough".Journal of thoracic disease · 2018Review
- Use of speckle tracking in the evaluation of late subclinical myocardial damage in survivors of childhood acute leukaemia.The international journal of cardiovascular imaging · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Owing to their high efficacy, anthracycline antibiotics are included in numerous chemotherapeutic regimens used-often in combination with radiation therapy and/or surgery-in treatment of solid tumours and blood malignancies, both in children and adults. However, the efficacy of modern cancer treatments, owing to which the population of cancer survivors has been on the rise in recent years, may be limited by the risk of serious complications involving multiple organs and systems, including the cardiovascular system. Being an important side effect of anthracyclines, cardiotoxicity may limit the efficacy of cancer therapies in the acute phase (i.e. during the treatment) and induce the long-term sequelae, observed years after treatment completion in childhood cancer survivors. It is very important to understand the cardiotoxicity-associated mechanisms and to determine its risk factors in order to develop and/or improve the effective countermeasures. Based on published data, the paper provides an outline of current views on anthracycline cardiotoxicity and discusses such aspects as molecular mechanisms of cardiotoxicity and its clinical manifestations as well as the new preventive strategies and diagnostic techniques used for the assessment of cardiovascular abnormalities. The widespread awareness of cancer treatment-related cardiotoxicity among the healthcare professionals may significantly improve the quality of life of the childhood cancer survivors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.